These findings highlight fucoxanthin’s potential to simultaneously target proliferative and metabolic pathways in FLT3-ITD AML, although the studied single-cell-line model (MOLM13) cannot fully represent FLT3-mutated AML heterogeneity and validation in primary samples is needed. Here, FLT3 is linked to acute myeloid leukemia.